Uzbekistan registered 28,719 newly diagnosed malignant neoplasms in 2025, equivalent to 76.5 cases per 100,000 residents.
Tashkent recorded the largest absolute number of new cases at 4,538. Tashkent region reported 2,950, Fergana 2,894, Namangan 2,438 and Andijan 2,359.
The capital also had the highest rate per 100,000 residents at 151.8. It was followed by Bukhara region at 96.4, Tashkent region at 94.8 and Navoi region at 82.5.
A high recorded incidence does not necessarily mean conditions are worse in a region. The figures are affected by population age, access to diagnostics, screening coverage and the quality of record-keeping. Patients from other regions are also referred to Tashkent, where specialist facilities are concentrated.
Newly diagnosed cases among children and adolescents fell by 24.5% over the year, from 827 to 624. Cases among children under 14 declined from 672 to 505, while the figure for those aged 15–17 dropped from 155 to 119.
About 260 billion Uzbek soum has been allocated in 2026 for centralised purchases of cancer, targeted, immunobiological, hormonal and supportive medicines.
An Islamic Development Bank oncology care project is valued at $80 million. By the end of 2025, 14 oncology institutions had received more than 1,700 units of equipment worth $62 million, including linear accelerators, MRI scanners, digital mammography machines and angiography systems.
Uzbekistan plans to begin a phased rollout of a national cancer control programme in 2027.
By 2030, the country plans to raise the share of cancers detected at an early stage to 40% and increase five-year patient survival from 35% to 45%.
